Johnson & Johnson - Company Snapshot & SWOT Analysis
Johnson & Johnson and its subsidiaries (the Company) have approximately 134,000 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, which has more than 260 operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a broad range of products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), Infectious Diseases and Vaccines (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders and schizophrenia), Oncology (e.g., prostate cancer and hematologic malignancies), Cardiovascular and Metabolism (e.g., thrombosis and diabetes) and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension), a new therapeutic area, which was established with the acquisition of Actelion in June 2017. Ana finally The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and eye health fields.
Johnson & Johnson is the largest healthcare company by revenue which generated a whopping USD 81.58 billion in total sales in 2018, and pharmaceuticals franchise were responsible for more than 50% of the conglomerate's top line. In 2018, annual consumer care franchise rose just 1.8% and the medical device segment generated a marginal 1.5% gain. Quite evidently, Johnson & Johnson's pharmaceutical run the show and pushed total revenue to 7% higher last year.
The Company expected to generate sales of $80.4 billion to $81.2 billion reflecting expected operational growth in the range of 0.0% to 1.0% and expected adjusted operational growth in the range of 2.0% to 3.0%.
Spanning over 31 pages and 14 exhibits, “Johnson & Johnson - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Johnson & Johnson - Company Snapshot & SWOT Analysis Report
This report provides detailed information about Johnson & Johnson including value chain analysis, financial performance, business strategy and SWOT analysis.
The report identifies the growth drivers and inhibitors for global pharmaceutical market.
This report provides information about current and future trends for global pharmaceutical market.
The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a broad range of products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), Infectious Diseases and Vaccines (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders and schizophrenia), Oncology (e.g., prostate cancer and hematologic malignancies), Cardiovascular and Metabolism (e.g., thrombosis and diabetes) and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension), a new therapeutic area, which was established with the acquisition of Actelion in June 2017. Ana finally The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and eye health fields.
Johnson & Johnson is the largest healthcare company by revenue which generated a whopping USD 81.58 billion in total sales in 2018, and pharmaceuticals franchise were responsible for more than 50% of the conglomerate's top line. In 2018, annual consumer care franchise rose just 1.8% and the medical device segment generated a marginal 1.5% gain. Quite evidently, Johnson & Johnson's pharmaceutical run the show and pushed total revenue to 7% higher last year.
The Company expected to generate sales of $80.4 billion to $81.2 billion reflecting expected operational growth in the range of 0.0% to 1.0% and expected adjusted operational growth in the range of 2.0% to 3.0%.
Spanning over 31 pages and 14 exhibits, “Johnson & Johnson - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Johnson & Johnson - Company Snapshot & SWOT Analysis Report
This report provides detailed information about Johnson & Johnson including value chain analysis, financial performance, business strategy and SWOT analysis.
The report identifies the growth drivers and inhibitors for global pharmaceutical market.
This report provides information about current and future trends for global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Johnson & Johnson- Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Johnson & Johnson
3.1.1. Company Profile
3.1.2 Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Johnson & Johnson: Financial Performance
3.1.4 Johnson & Johnson: Geography wise Performance
3.1.5 Johnson & Johnson: Business Strategy
3.1.5.1 Johnson & Johnson Revenue by Business Segment
3.1.6 SWOT Analysis of Johnson & Johnson
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Company Information
Scope of the Johnson & Johnson- Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Johnson & Johnson
3.1.1. Company Profile
3.1.2 Johnson & Johnson in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Johnson & Johnson: Financial Performance
3.1.4 Johnson & Johnson: Geography wise Performance
3.1.5 Johnson & Johnson: Business Strategy
3.1.5.1 Johnson & Johnson Revenue by Business Segment
3.1.6 SWOT Analysis of Johnson & Johnson
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Company Information
LIST OF EXHIBITS
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Johnson & Johnson
Exhibit 3.2 Contact information of Johnson & Johnson
Exhibit 3.3 Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
Exhibit 3.6 Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 3.7 Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 3.8 Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 3.9 Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 3.10 Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 3.11 Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 3.12 Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)
Exhibit 3.13 SWOT Analysis of Johnson & Johnson
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Johnson & Johnson
Exhibit 3.2 Contact information of Johnson & Johnson
Exhibit 3.3 Johnson & Johnson in Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Revenue of Johnson & Johnson FY 2013- FY 2019 (in USD billion)
Exhibit 3.5 Revenue Growth of Johnson & Johnson FY 2014- FY 2019 (in %)
Exhibit 3.6 Division-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 3.7 Consumer Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 3.8 Pharmaceuticals Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 3.9 Medical Devices Division Revenue of Johnson & Johnson FY 2013- FY 2018 (in USD billion)
Exhibit 3.10 Geography-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 3.11 Therapy Area-Wise Revenue of Johnson & Johnson in FY 2018 (in USD billion)
Exhibit 3.12 Therapy and Geography Area-Wise Revenue of Johnson & Johnson FY 2018 (in USD billion)
Exhibit 3.13 SWOT Analysis of Johnson & Johnson
